BeiGene Product Portfolio and Pipeline

Three Marketed Products in China, Three Late-Stage Assets, and Five Early-Stage Clinical Assets

Global
China



*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. ***REVLIMID® approved as a combination therapy with dexamethasone. 1. Celgene has the right to develop and commercialize tislelizumab in solid tumors in the U.S., EU, Japan and the rest-of-world outside of Asia. 2. Limited collaboration with Merck KGaA. 3.Collaboration with Mirati Therapeutics, Inc.

BeiGene